Workplace interventions to reduce the risk of SARS-CoV-2 infection outside of healthcare settings.
Journal
The Cochrane database of systematic reviews
ISSN: 1469-493X
Titre abrégé: Cochrane Database Syst Rev
Pays: England
ID NLM: 100909747
Informations de publication
Date de publication:
06 05 2022
06 05 2022
Historique:
entrez:
6
5
2022
pubmed:
7
5
2022
medline:
10
5
2022
Statut:
epublish
Résumé
Although many people infected with SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2) experience no or mild symptoms, some individuals can develop severe illness and may die, particularly older people and those with underlying medical problems. Providing evidence-based interventions to prevent SARS-CoV-2 infection has become more urgent with the spread of more infectious SARS-CoV-2 variants of concern (VoC), and the potential psychological toll imposed by the coronavirus disease 2019 (COVID-19) pandemic. Controlling exposures to occupational hazards is the fundamental method of protecting workers. When it comes to the transmission of viruses, such as SARS-CoV-2, workplaces should first consider control measures that can potentially have the most significant impact. According to the hierarchy of controls, one should first consider elimination (and substitution), then engineering controls, administrative controls, and lastly, personal protective equipment (PPE). To assess the benefits and harms of interventions in non-healthcare-related workplaces to reduce the risk of SARS-CoV-2 infection relative to other interventions, or no intervention. We searched MEDLINE, Embase, Web of Science, Cochrane COVID-19 Study Register, the Canadian Centre for Occupational Health and Safety (CCOHS), Clinicaltrials.gov, and the International Clinical Trials Registry Platform to 14 September 2021. We will conduct an update of this review in six months. We included randomised control trials (RCT) and planned to include non-randomised studies of interventions. We included adult workers, both those who come into close contact with clients or customers (e.g. public-facing employees, such as cashiers or taxi drivers), and those who do not, but who could be infected by co-workers. We excluded studies involving healthcare workers. We included any intervention to prevent or reduce workers' exposure to SARS-CoV-2 in the workplace, defining categories of intervention according to the hierarchy of hazard controls, i.e. elimination; engineering controls; administrative controls; personal protective equipment. We used standard Cochrane methods. Our primary outcomes were incidence rate of SARS-CoV-2 infection (or other respiratory viruses), SARS-CoV-2-related mortality, adverse events, and absenteeism from work. Our secondary outcomes were all-cause mortality, quality of life, hospitalisation, and uptake, acceptability, or adherence to strategies. We used the Cochrane RoB 2 tool to assess the risk of bias, and GRADE methods to assess the certainty of evidence for each outcome. Elimination of exposure interventions We included one study examining an intervention that focused on elimination of hazards. This study is an open-label, cluster-randomised, non-inferiority trial, conducted in England in 2021. The study compared standard 10-day self-isolation after contact with an infected person to a new strategy of daily rapid antigen testing and staying at work if the test is negative (test-based attendance). The trialists hypothesised that this would lead to a similar rate of infections, but lower COVID-related absence. Staff (N = 11,798) working at 76 schools were assigned to standard isolation, and staff (N = 12,229) at 86 schools to the test-based attendance strategy. The results between test-based attendance and standard 10-day self-isolation were inconclusive for the rate of symptomatic PCR-positive SARS-COV-2 infection rate ratio ((RR) 1.28, 95% confidence interval (CI) 0.74 to 2.21; 1 study, very low-certainty evidence)). The results between test-based attendance and standard 10-day self-isolation were inconclusive for the rate of any PCR-positive SARS-COV-2 infection (RR 1.35, 95% CI 0.82 to 2.21; 1 study, very low-certainty evidence). COVID-related absenteeism rates were 3704 absence days in 566,502 days-at-risk (6.5 per 1000 days at risk) in the control group and 2932 per 539,805 days-at-risk (5.4 per 1000 days at risk) in the intervention group (RR 0.83; 95% CI 0.55 to 1.25). The certainty of the evidence was downgraded to low, due to imprecision. Uptake of the intervention was 71 % in the intervention group, but not reported for the control intervention. The trial did not measure other outcomes, SARS-CoV-2-related mortality, adverse events, all-cause mortality, quality of life, and hospitalisation. We found one ongoing RCT about screening in schools, using elimination of hazard strategies. Personal protective equipment We found one ongoing non-randomised study on the effects of closed face shields to prevent COVID-19 transmission. Other intervention categories We did not find studies in the other intervention categories. We are uncertain whether a test-based attendance policy affects rates of PCR-postive SARS-CoV-2 infection (any infection; symptomatic infection) compared to standard 10-day self-isolation amongst school and college staff. Test-based attendance policy may result in little to no difference in absence rates compared to standard 10-day self-isolation. As a large part of the population is exposed in the case of a pandemic, an apparently small relative effect that would not be worthwhile from the individual perspective may still affect many people, and thus, become an important absolute effect from the enterprise or societal perspective. The included study did not report on any other primary outcomes of our review, i.e. SARS-CoV-2-related mortality and adverse events. No completed studies were identified on any other interventions specified in this review, but two eligible studies are ongoing. More controlled studies are needed on testing and isolation strategies, and working from home, as these have important implications for work organisations.
Sections du résumé
BACKGROUND
Although many people infected with SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2) experience no or mild symptoms, some individuals can develop severe illness and may die, particularly older people and those with underlying medical problems. Providing evidence-based interventions to prevent SARS-CoV-2 infection has become more urgent with the spread of more infectious SARS-CoV-2 variants of concern (VoC), and the potential psychological toll imposed by the coronavirus disease 2019 (COVID-19) pandemic. Controlling exposures to occupational hazards is the fundamental method of protecting workers. When it comes to the transmission of viruses, such as SARS-CoV-2, workplaces should first consider control measures that can potentially have the most significant impact. According to the hierarchy of controls, one should first consider elimination (and substitution), then engineering controls, administrative controls, and lastly, personal protective equipment (PPE).
OBJECTIVES
To assess the benefits and harms of interventions in non-healthcare-related workplaces to reduce the risk of SARS-CoV-2 infection relative to other interventions, or no intervention.
SEARCH METHODS
We searched MEDLINE, Embase, Web of Science, Cochrane COVID-19 Study Register, the Canadian Centre for Occupational Health and Safety (CCOHS), Clinicaltrials.gov, and the International Clinical Trials Registry Platform to 14 September 2021. We will conduct an update of this review in six months.
SELECTION CRITERIA
We included randomised control trials (RCT) and planned to include non-randomised studies of interventions. We included adult workers, both those who come into close contact with clients or customers (e.g. public-facing employees, such as cashiers or taxi drivers), and those who do not, but who could be infected by co-workers. We excluded studies involving healthcare workers. We included any intervention to prevent or reduce workers' exposure to SARS-CoV-2 in the workplace, defining categories of intervention according to the hierarchy of hazard controls, i.e. elimination; engineering controls; administrative controls; personal protective equipment.
DATA COLLECTION AND ANALYSIS
We used standard Cochrane methods. Our primary outcomes were incidence rate of SARS-CoV-2 infection (or other respiratory viruses), SARS-CoV-2-related mortality, adverse events, and absenteeism from work. Our secondary outcomes were all-cause mortality, quality of life, hospitalisation, and uptake, acceptability, or adherence to strategies. We used the Cochrane RoB 2 tool to assess the risk of bias, and GRADE methods to assess the certainty of evidence for each outcome.
MAIN RESULTS
Elimination of exposure interventions We included one study examining an intervention that focused on elimination of hazards. This study is an open-label, cluster-randomised, non-inferiority trial, conducted in England in 2021. The study compared standard 10-day self-isolation after contact with an infected person to a new strategy of daily rapid antigen testing and staying at work if the test is negative (test-based attendance). The trialists hypothesised that this would lead to a similar rate of infections, but lower COVID-related absence. Staff (N = 11,798) working at 76 schools were assigned to standard isolation, and staff (N = 12,229) at 86 schools to the test-based attendance strategy. The results between test-based attendance and standard 10-day self-isolation were inconclusive for the rate of symptomatic PCR-positive SARS-COV-2 infection rate ratio ((RR) 1.28, 95% confidence interval (CI) 0.74 to 2.21; 1 study, very low-certainty evidence)). The results between test-based attendance and standard 10-day self-isolation were inconclusive for the rate of any PCR-positive SARS-COV-2 infection (RR 1.35, 95% CI 0.82 to 2.21; 1 study, very low-certainty evidence). COVID-related absenteeism rates were 3704 absence days in 566,502 days-at-risk (6.5 per 1000 days at risk) in the control group and 2932 per 539,805 days-at-risk (5.4 per 1000 days at risk) in the intervention group (RR 0.83; 95% CI 0.55 to 1.25). The certainty of the evidence was downgraded to low, due to imprecision. Uptake of the intervention was 71 % in the intervention group, but not reported for the control intervention. The trial did not measure other outcomes, SARS-CoV-2-related mortality, adverse events, all-cause mortality, quality of life, and hospitalisation. We found one ongoing RCT about screening in schools, using elimination of hazard strategies. Personal protective equipment We found one ongoing non-randomised study on the effects of closed face shields to prevent COVID-19 transmission. Other intervention categories We did not find studies in the other intervention categories.
AUTHORS' CONCLUSIONS
We are uncertain whether a test-based attendance policy affects rates of PCR-postive SARS-CoV-2 infection (any infection; symptomatic infection) compared to standard 10-day self-isolation amongst school and college staff. Test-based attendance policy may result in little to no difference in absence rates compared to standard 10-day self-isolation. As a large part of the population is exposed in the case of a pandemic, an apparently small relative effect that would not be worthwhile from the individual perspective may still affect many people, and thus, become an important absolute effect from the enterprise or societal perspective. The included study did not report on any other primary outcomes of our review, i.e. SARS-CoV-2-related mortality and adverse events. No completed studies were identified on any other interventions specified in this review, but two eligible studies are ongoing. More controlled studies are needed on testing and isolation strategies, and working from home, as these have important implications for work organisations.
Identifiants
pubmed: 35514111
doi: 10.1002/14651858.CD015112.pub2
pmc: PMC9073086
doi:
Banques de données
ClinicalTrials.gov
['NCT04647305', 'NCT04878809']
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
CD015112Informations de copyright
Copyright © 2022 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Références
Eur Respir J. 2022 Feb 3;59(2):
pubmed: 34210789
Cochrane Database Syst Rev. 2020 Dec 17;12:CD013812
pubmed: 33331665
MMWR Morb Mortal Wkly Rep. 2021 Mar 12;70(10):350-354
pubmed: 33705364
J Occup Environ Med. 2021 Apr 1;63(4):e245-e249
pubmed: 33560072
Environ Sci Pollut Res Int. 2021 Feb;28(6):6267-6288
pubmed: 33387315
BMJ. 2021 Nov 17;375:e068302
pubmed: 34789505
Sci Adv. 2022 Feb 25;8(8):eabm3608
pubmed: 35213224
Cochrane Database Syst Rev. 2020 May 15;5:CD011621
pubmed: 32412096
BMJ. 2020 Jan 16;368:l6890
pubmed: 31948937
Emerg Infect Dis. 2021 Apr;27(4):1032-1038
pubmed: 33591249
Cochrane Database Syst Rev. 2021 Mar 25;3:CD013717
pubmed: 33763851
J Occup Rehabil. 2020 Sep;30(3):299-302
pubmed: 32562129
Emerg Infect Dis. 2019 Jan;25(1):1-4
pubmed: 30560777
JAMA. 2020 Oct 6;324(13):1348-1349
pubmed: 32808979
Prev Med Rep. 2021 Sep;23:101471
pubmed: 34221853
Clin Infect Dis. 2021 Feb 16;72(4):598-603
pubmed: 32594121
Microb Risk Anal. 2020 Dec;16:100137
pubmed: 32904602
J Occup Environ Med. 2021 Jul 1;63(7):548-556
pubmed: 33741830
PLoS One. 2020 Dec 9;15(12):e0241956
pubmed: 33296367
Lancet Child Adolesc Health. 2020 May;4(5):397-404
pubmed: 32272089
Lancet. 2021 Oct 2;398(10307):1217-1229
pubmed: 34534517
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Dan Med J. 2020 Aug 18;67(9):
pubmed: 32829745
Emerg Infect Dis. 2021 Jan;27(1):
pubmed: 33075274
Cochrane Database Syst Rev. 2020 Apr 21;4:CD013582
pubmed: 32315451
Proc Natl Acad Sci U S A. 2020 Dec 15;117(50):31706-31715
pubmed: 33214147
Toxicol Ind Health. 2020 Sep;36(9):689-702
pubmed: 33241763
Tex Med. 2020 Aug 1;116(8):30-31
pubmed: 32866272
J Glob Health. 2020 Dec;10(2):020381
pubmed: 33214890
Ann Work Expo Health. 2020 Jun 24;64(5):461-464
pubmed: 32202635
J Infect Dis. 2020 May 11;221(11):1757-1761
pubmed: 32067043
Cochrane Database Syst Rev. 2020 Oct 12;10:CD013686
pubmed: 33047816
N Engl J Med. 2020 Oct 29;383(18):1757-1766
pubmed: 32329974
Vet Rec. 2020 Jul;187(1):34-35
pubmed: 33638492
J Hosp Infect. 2021 May;111:6-26
pubmed: 33744382
BMJ. 2016 Oct 12;355:i4919
pubmed: 27733354
Ann Intern Med. 2021 Mar;174(3):335-343
pubmed: 33205991
N Engl J Med. 2020 Dec 17;383(25):2451-2460
pubmed: 32412710
J Med Internet Res. 2021 Mar 10;23(3):e23365
pubmed: 33606657
Cochrane Database Syst Rev. 2020 Nov 20;11:CD006207
pubmed: 33215698
J Assoc Med Microbiol Infect Dis Can. 2020 Dec 31;5(4):223-234
pubmed: 36340059
Int J Infect Dis. 2020 Dec;101:138-148
pubmed: 33007452
Int J Epidemiol. 2002 Feb;31(1):140-9
pubmed: 11914310
BMJ. 2020 Jul 9;370:m2716
pubmed: 32646892
Science. 2021 Mar 12;371(6534):1103-1104
pubmed: 33707254
Int J Environ Res Public Health. 2021 Jul 24;18(15):
pubmed: 34360142
PLoS Biol. 2020 Nov 12;18(11):e3000897
pubmed: 33180773
Cochrane Database Syst Rev. 2022 May 6;5:CD015112
pubmed: 35514111
Cochrane Database Syst Rev. 2020 Sep 16;9:CD013626
pubmed: 32936949
Cochrane Database Syst Rev. 2020 Sep 16;9:CD013627
pubmed: 32936948
BMJ. 2019 Aug 28;366:l4898
pubmed: 31462531
Int J Environ Res Public Health. 2021 Mar 05;18(5):
pubmed: 33807936
Elife. 2021 Jul 13;10:
pubmed: 33904403
JAMA. 2021 Apr 6;325(13):1251-1252
pubmed: 33662101
EMBO Mol Med. 2020 Dec 7;12(12):e13296
pubmed: 33012091
J Med Virol. 2020 Sep;92(9):1567-1571
pubmed: 32232986
J Occup Environ Med. 2020 Nov;62(11):e665-e668
pubmed: 32858555
J Occup Environ Med. 2021 Mar 1;63(3):199-220
pubmed: 33350662
Occup Environ Med. 2020 May;77(5):281-282
pubmed: 32238444
J Infect. 2021 Sep;83(3):281-293
pubmed: 34161818
Ann Intern Med. 2020 May 05;172(9):577-582
pubmed: 32150748
Aerosp Med Hum Perform. 2021 Apr 1;92(4):274-280
pubmed: 33752791
Lancet Public Health. 2020 Sep;5(9):e475-e483
pubmed: 32745512
PLoS Med. 2021 Mar 11;18(3):e1003564
pubmed: 33705396
Nat Hum Behav. 2020 Dec;4(12):1303-1312
pubmed: 33199859
Hum Factors Ergon Manuf. 2021 Jul;31(4):375-388
pubmed: 33821126
Infect Control Hosp Epidemiol. 1999 Mar;20(3):200-2
pubmed: 10100548
Cochrane Database Syst Rev. 2020 Sep 16;9:CD013628
pubmed: 32936947
Ann Intern Med. 2020 Jul 21;173(2):120-136
pubmed: 32369541
Ann Intern Med. 2021 May;174(5):655-662
pubmed: 33481642
Am J Respir Crit Care Med. 2021 Jun 15;203(12):1462-1471
pubmed: 33835905
Stat Med. 2001 Feb 15;20(3):391-9
pubmed: 11180309